Who are Promacta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mulpleta, Doptelet, Nplate, CsA+ATG+Herombopag, CsA+Herombopag, rhTPO combined with Herombopag + CsA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eltrombopag.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Promacta — Competitive Intelligence Brief

Promacta (ELTROMBOPAG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombopoietin Receptor Agonist. Area: Oncology.

marketed Thrombopoietin Receptor Agonist Thrombopoietin receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Promacta (ELTROMBOPAG) — Novartis. Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Promacta TARGET	ELTROMBOPAG	Novartis	marketed	Thrombopoietin Receptor Agonist	Thrombopoietin receptor	2008-01-01
Mulpleta	LUSUTROMBOPAG	Vancocin Italia	marketed		Thrombopoietin receptor	2018-01-01
Doptelet	AVATROMBOPAG	Akarx Inc	marketed		Thrombopoietin receptor	2018-01-01
Nplate	ROMIPLOSTIM	Amgen	marketed	Thrombopoietin Receptor Agonist [EPC]	Thrombopoietin receptor	2008-01-01
CsA+ATG+Herombopag	CsA+ATG+Herombopag	Peking Union Medical College Hospital	marketed	Immunosuppressive agent + thrombopoietin receptor agonist combination	Calcineurin (CsA); T lymphocytes (ATG); thrombopoietin receptor (eltrombopag)
CsA+Herombopag	CsA+Herombopag	Peking Union Medical College Hospital	marketed	Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist	Calcineurin (CsA); thrombopoietin receptor / MPL (herombopag)
rhTPO combined with Herombopag + CsA	rhTPO combined with Herombopag + CsA	Peking Union Medical College Hospital	marketed	Thrombopoietin receptor agonist combination with immunosuppressant	Thrombopoietin receptor (MPL); calcineurin (CsA target)

Recent regulatory actions (last 90 days)

2026-03-16 — Promacta · FDA · approved · US · Novartis

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombopoietin Receptor Agonist class)

Novartis · 1 drug in this class
The First Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Promacta — Competitive Intelligence Brief. https://druglandscape.com/ci/eltrombopag. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab